Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
AssigneesSeoul National University R&Db Foundation, University of Ulsan, Korea Institute of Science and Technology, Pharosgen
InventorsYoungro Byun, In San Kim, Ahmed Al-Hilal Taslim, Sang-Yoon Kim, Ye Ji Jang
Life of this patent
Estimating the term…
Abstract
Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
Claims18
An antibody that binds to doppel or a doppel-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein:
- (a) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO:
- 31;
- a CDRH2 comprising the amino acid sequence of SEQ ID NO:
- 32;
- and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
- 33;
- and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO:
- 13;
- a CDRL2 comprising the amino acid sequence of SEQ ID NO:
- 14;
- and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
- 15;
- (b) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO:
- 34;
- a CDRH2 comprising the amino acid sequence of SEQ ID NO:
- 35;
- and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
- 36;
- and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO:
- 16;
- a CDRL2 comprising the amino acid sequence of SEQ ID NO:
- 17;
- and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
- 18;
- (c) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO:
- 37;
- a CDRH2 comprising the amino acid sequence of SEQ ID NO:
- 38;
- and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
- 39;
- and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO:
- 19;
- a CDRL2 comprising the amino acid sequence of SEQ ID NO:
- 20;
- and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
- 21;
- (d) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO:
- 40;
- a CDRH2 comprising the amino acid sequence of SEQ ID NO:
- 41;
- and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
- 42;
- and the light chain variable region comprises a CDRL1 comprising the amino acid sequence of SEQ ID NO:
- 22;
- a CDRL2 comprising the amino acid sequence of SEQ ID NO:
- 23;
- and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
- 24;
- or
- (e) the heavy chain variable region comprises a CDRH1 comprising the amino acid sequence of SEQ ID NO:
- 43;
- a CDRH2 comprising the amino acid sequence of SEQ ID NO:
- 44;
- and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
- 45;
- and the light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
- 25;
- a CDRL2 comprising the amino acid sequence of SEQ ID NO:
- 26;
- and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
- 27.
Dependencies are inferred from the claim text.